GENE ONLINE|News &
Opinion
Blog

2022-11-01| Trials & Approvals

Santhera, ReveraGen’s Duchenne Drug Accepted By EMA While Anticipating FDA Priority Review

by Joy Lin
Share To

Swiss biotech Santhera and its partner ReveraGen have announced that the European Medicines Agency (EMA) has accepted their marketing authorization application (MAA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). Vamorolone, positioned as an alternative to current corticosteroids, will now be reviewed by EMA’s Committee for Medicinal Products for Human Use (CHMP). 

Santhera is expecting a positive opinion from the CHMP recommending vamorolone for European Commission (EC) approval in late Q3 2023, according to the company’s press release

In the US, Santhera and ReveraGen have completed the new drug application (NDA) filing to the US FDA. The companies are seeking priority review and will know in 60 days if the FDA has granted their application. If granted, vamorolone will be set to become available to patients in the US in the second half of 2023, Santhera said

Read More: Janssen Drops Out of Prostate Cancer Clinical Trial Due to Lack of Patients

Primary Endpoint Met 

Vamorolone is a synthetic steroid designed to bind to the same receptor as corticosteroids to exert anti-inflammatory activity and counter the progressive muscle degeneration caused by Duchenne. 

In the pivotal VISION-DMD study assessing vamorolone in two doses for Duchenne, the drug met the primary endpoint of Stand velocity versus placebo at 24 weeks of treatment. In the high-dose arm (6 mg/kg a day) vamorolone-treated patients reduced the time from lying flat to standing from 6 seconds to 4.6 seconds, compared to the placebo (5.4 seconds to 5.5 seconds).

Adverse events ranging from mild to moderate severity included cushingoid features, vomiting, and vitamin D deficiency. 

Delays For The Duchenne Drug

Santhera’s attempts to get a Duchenne treatment into the market have been met with setbacks and delays. The company was forced to restructure and focus on vamorolone after their now-defunct DMD drug idebenone failed an interim analysis in Phase 3 in 2020.

In late June, vamorolone’s rolling submission to the FDA hit a bump after Santhera’s third-party contract manufacturing partner said it could not prepare the drug for FDA inspection, which pushed the regulatory timeline for the drug back by several months.  

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition
2025-06-18
GSK Scores FDA Approval for Nucala as Add-On Treatment to Reduce COPD Exacerbations
2025-05-23
CRISPR Makes History with First One-of-a-Kind Gene Therapy for Infant
2025-05-19
LATEST
Arkansas Bans Pharmacy Benefit Managers from Owning Pharmacies
2025-07-14
Air Pollution, Inequality, and Weak Democracies Linked to Faster Aging in Global Study
2025-07-14
Analysis Reveals Publication Bias in Scientific Research Dates Back to Modern Science’s Origins
2025-07-14
Oncology Pharmacists Tackle Biosimilar Integration and 505(b)(2) Drug Adoption at ATOPP 2025 Conference
2025-07-14
Pneumococcal Vaccination Linked to Lower Risk of Severe COVID-19 Outcomes in Patients with Inflammatory Rheumatic Diseases
2025-07-14
Telepharmacy and Mobile Units Address Medication Access in Pharmacy Deserts
2025-07-14
Board-Certified Psychiatric Pharmacists Address Behavioral Health Workforce Shortages with Expertise in Psychopharmacology
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top